Evoke Net Receivables from 2010 to 2026

EVOK Stock  USD 30.10  0.40  1.35%   
Evoke Pharma Net Receivables yearly trend continues to be quite stable with very little volatility. Net Receivables may rise above about 2.9 M this year. From the period between 2010 and 2026, Evoke Pharma, Net Receivables regression line of its data series had standard deviation of  1,037,719 and standard deviation of  1,037,719. View All Fundamentals
 
Net Receivables  
First Reported
2020-09-30
Previous Quarter
2.9 M
Current Value
3.2 M
Quarterly Volatility
996.4 K
 
Covid
 
Interest Hikes
Check Evoke Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Evoke Pharma's main balance sheet or income statement drivers, such as Depreciation And Amortization of 5.6 M, Interest Expense of 605.4 K or Selling General Administrative of 18.2 M, as well as many indicators such as Price To Sales Ratio of 0.9, Dividend Yield of 0.0 or PTB Ratio of 2.74. Evoke financial statements analysis is a perfect complement when working with Evoke Pharma Valuation or Volatility modules.
  
Build AI portfolio with Evoke Stock
Check out the analysis of Evoke Pharma Correlation against competitors.
For more information on how to buy Evoke Stock please use our How to buy in Evoke Stock guide.
Historical Net Receivables data for Evoke Pharma serves as a key indicator of operational performance and financial stability. Tracking changes in this metric over time helps investors spot emerging trends before they become obvious, providing an edge in assessing whether Evoke Pharma represents a compelling investment opportunity.

Latest Evoke Pharma's Net Receivables Growth Pattern

Below is the plot of the Net Receivables of Evoke Pharma over the last few years. It is Evoke Pharma's Net Receivables historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Evoke Pharma's overall financial position and show how it may be relating to other accounts over time.
Net Receivables10 Years Trend
Slightly volatile
   Net Receivables   
       Timeline  

Evoke Net Receivables Regression Statistics

Arithmetic Mean586,819
Geometric Mean92,587
Coefficient Of Variation176.84
Mean Deviation763,554
Median23,311
Standard Deviation1,037,719
Sample Variance1.1T
Range2.9M
R-Value0.76
Mean Square Error492.5B
R-Squared0.57
Significance0.0004
Slope155,314
Total Sum of Squares17.2T

Evoke Net Receivables History

20262.9 M
20252.8 M
20242.4 M
2023673.1 K
2022624.8 K
2021295.2 K

About Evoke Pharma Financial Statements

Evoke Pharma investors utilize fundamental indicators, such as Net Receivables, to predict how Evoke Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Net Receivables2.8 M2.9 M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Prophet
When determining whether Evoke Pharma is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Evoke Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Evoke Pharma Stock. Highlighted below are key reports to facilitate an investment decision about Evoke Pharma Stock:
Check out the analysis of Evoke Pharma Correlation against competitors.
For more information on how to buy Evoke Stock please use our How to buy in Evoke Stock guide.
You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Evoke Pharma. Projected growth potential of Evoke fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Evoke Pharma assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share
(1.38)
Revenue Per Share
5.182
Quarterly Revenue Growth
0.614
Return On Assets
(0.22)
Return On Equity
(1.35)
Investors evaluate Evoke Pharma using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Evoke Pharma's intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. External factors like market trends, sector rotation, and investor psychology can cause Evoke Pharma's market price to deviate significantly from intrinsic value.
It's important to distinguish between Evoke Pharma's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Evoke Pharma should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, Evoke Pharma's market price signifies the transaction level at which participants voluntarily complete trades.